Parasym Launches Nuropod Non-Invasive Vagus Nerve Stimulation Device

Parasym has introduced Nuropod to the U.S. market, marking the arrival of the first clinically studied, ear-based vagus nerve stimulation (VNS) device that eliminates the need for surgical intervention. The wearable technology leverages Auricular Vagal Neuromodulation Technology (AVNT), a proprietary method that targets the vagus nerve through the ear to activate the body's parasympathetic nervous system and restore the "rest and digest" state.

The device addresses a significant gap in VNS accessibility, as traditional approaches have required costly surgical implants. Vagus nerve stimulation regulates the autonomic nervous system, which serves as the body's command center for stress response, recovery, and inflammation control. Peer-reviewed studies indicate that AVNT matches or exceeds the effectiveness of surgical VNS methods while offering a non-invasive alternative.

Dr. Elisabetta Burchi, Parasym's Head of Research, emphasized the device's potential impact on widespread health challenges. "Nearly one in three Americans reports feeling constantly fatigued, and the average adult in the U.S. has more than 40 hours of sleep debt each month," she noted, highlighting the device's role in helping people reset their nervous systems.

Clinical validation for AVNT comes from multiple randomized, placebo-controlled studies that demonstrate measurable physiological improvements. Research findings show a 61% increase in vagus nerve activity within five minutes of use, alongside a 78% reduction in bodily inflammation. Additional documented benefits include a 48% decrease in fatigue, 19% improvement in sleep quality, 35% reduction in anxious thoughts, and 32% enhancement in memory function.

The technology has undergone extensive research through collaborations with Harvard and UCLA, examining its applications for reducing inflammation, improving cardiovascular function, enhancing cognitive performance, and alleviating fatigue associated with conditions including long COVID and postural orthostatic tachycardia syndrome (POTS). The FDA has granted Nuropod a Non-Significant Risk Designation, confirming its safety profile for consumer use.

Nuropod is now available direct-to-consumer at $900, bringing clinically proven VNS technology that was previously accessible only through surgical procedures to a broader audience. The device accommodates various user needs, from professional athletes monitoring recovery to individuals seeking symptom relief from persistent health conditions.

Click here for the original news story.